Name | Title | Contact Details |
---|---|---|
Aasim Javed |
Chief Financial Officer | Profile |
Suzanne Stone |
Chief Commercial Officer | Profile |
Dawn Moskop |
Director of Brand Marketing and Creative | Profile |
Emmanuel Callias |
Senior Director, Human Resources | Profile |
ChiHui Liang |
Sr. Director of Research Development | Profile |
At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow`s breakthrough treatments. GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company`s inception in 2003, we have developed a robust, diversified product pipeline. We are a public company traded on the NASDAQ under the symbol GLYC.
AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Improving lives by enhancing precision cancer diagnostics.
BioNJ is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Icagen is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.